Anti-VEGF injection billing: units, JW/JZ waste, and the coverage article that actually governs the drug line.
A 67028 injection claim rarely denies over the injection code itself. It denies because the drug line was wrong — the wrong HCPCS for the product given, a missing JW or JZ, units that don't match the milligram math, or a diagnosis missing the laterality and stage a drug-specific coding article expects. This guide works the drug line the way an auditor reads it.
Key takeaways
- CMS publishes drug-specific coding articles for anti-VEGF agents — four confirmed active across three MACs, cited by document ID below.
- JW and JZ are not interchangeable defaults. One reports discarded drug, the other attests to none, and CMS requires one of the two on every single-dose-container line — no exception for "we always use the whole vial."
- The diagnosis code has to carry laterality and stage, not just the disease. Wet AMD, diabetic macular edema, and retinal vein occlusion each verify to a specific eye- and activity-coded branch — an unspecified-eye code is the most avoidable reason a correctly-dosed claim still denies.
- Step therapy is a plan-level rule, not a Medicare rule. Traditional fee-for-service Medicare doesn't require a bevacizumab trial before aflibercept or faricimab; many commercial and MA plans do, and treating the two as interchangeable is a routine prior-auth denial.
HCPCS by product, and how to compute units
67028 (intravitreal injection), billed once per eye per date of service, carries little denial risk once the eye and date are right. The drug line is where risk concentrates: the HCPCS code has to match the product administered, the units have to match the milligram dose under that code's unit definition, and the waste modifier has to describe the rest of the vial correctly. Report the NDC for the specific product given, not the reference product out of habit — ranibizumab and aflibercept both now have biosimilar entrants carrying their own distinct codes.
| HCPCS | Drug | Unit basis and example |
|---|---|---|
J0178 | Aflibercept (Eylea) | Per 1 mg — a 2 mg dose bills as 2 units |
J0177 | Aflibercept, high-dose (Eylea HD) | Per 1 mg, distinct code from standard-dose aflibercept — never bill J0178 for the HD formulation |
J2778 | Ranibizumab (Lucentis) and its interchangeable biosimilars | Per 0.1 mg — a 0.3 mg dose bills as 3 units, a 0.5 mg dose as 5 units |
J2777 | Faricimab (Vabysmo) | Per 0.1 mg — a 6 mg dose bills as 60 units |
J9035 | Bevacizumab (Avastin), off-label ophthalmic use | Per 10 mg descriptor; many payers instead require an ophthalmic-specific compounded code — confirm before billing |
C9257 | Bevacizumab, 0.25 mg — hospital outpatient (OPPS) | Distinct unit size from J9035; facility billing only |
JW and JZ: the waste documentation CMS actually requires
Both modifiers apply only to single-dose containers, and CMS requires one on every applicable line — no option to leave it blank. JW reports a measurable discarded amount. JZ attests that nothing was discarded. Defaulting to JW out of habit on a no-waste claim is a routine, self-inflicted denial in practices that never updated the workflow once JZ became mandatory.
Worked example. A single-dose vial labeled 0.5 mg of ranibizumab is opened, and the order calls for 0.3 mg. The claim reports J2778 with 3 units for the dose given, plus a second line, J2778-JW, with 2 units for the 0.2 mg discarded from that container. If the full labeled 0.5 mg had instead been the ordered dose, there is no discard and no second line — the single line reports J2778-JZ with 5 units.
JW and JZ still apply under white bagging, where a specialty pharmacy ships the dose directly to the practice. The practice still administered from a single-dose container, so the attestation is still owed — a gap practices miss because white-bagged lines get less coding attention than a buy-and-bill line.
Diagnosis coding: laterality and stage decide coverage
The three highest-volume anti-VEGF indications each verify to a specific ICD-10-CM branch carrying laterality and a disease-activity qualifier, not just the diagnosis category. Coding to the unspecified code is the most avoidable reason a correctly-dosed, correctly-modified drug claim still denies on medical necessity.
| Indication | Unspecified (avoid as primary) | Specific, billable branch |
|---|---|---|
| Wet (exudative) AMD | H35.3290 unspecified eye, stage unspecified | H35.3211–H35.3213 right · H35.3221–H35.3223 left · H35.3231–H35.3233 bilateral — each split by active, inactive, or scarred neovascularization |
| Diabetic macular edema (type 2) | E11.9 without complications | E11.311 unspecified retinopathy with macular edema, by laterality, through the mild/moderate/severe and proliferative branches — full crosswalk in our ophthalmology billing guide |
| Retinal vein occlusion | H34.819 central RVO, unspecified eye | H34.8110/H34.8120/H34.8130 central RVO with edema by right/left/bilateral eye · equivalent branches under H34.83 for branch RVO |
Wet AMD and RVO both carry that activity qualifier — active versus inactive/scarred for AMD, edema-present versus stable for RVO — and coverage criteria are frequently written against it, not just the base diagnosis. A stable case still coded as active draws the same scrutiny as an unspecified code, because the diagnosis no longer matches what continued injections are treating.
The coverage articles that actually govern anti-VEGF billing
Anti-VEGF drugs have their own coding articles, published per MAC, distinct from the general LCDs covering cataract, imaging, and blepharoplasty listed in the pillar guide:
| Article | Title | MAC | Effective date |
|---|---|---|---|
A52451 | Billing and Coding: Ranibizumab, Aflibercept and biosimilars | Wellpoint Federal | 07/01/2026 |
A53387 | Billing and Coding: Aflibercept (EYLEA®) | Palmetto GBA | 07/01/2026 |
A52370 | Billing and Coding: Bevacizumab and biosimilars | Wellpoint Federal | 07/01/2026 |
A53008 | Billing and Coding: Intraocular Bevacizumab | Noridian Healthcare Solutions | 11/06/2025 |
⚠️ Document IDs, titles, contractors, and effective dates above were confirmed live against the CMS Coverage Database. Each article's internal covered-diagnosis lists and unit/NDC instructions were not independently re-verified line by line (CMS's article pages returned access errors to automated retrieval), so pull your MAC's article text before finalizing a rule against it. If your MAC isn't listed, search the Coverage Database by contractor and drug name — coverage is documented per-MAC, not nationally.
Step therapy and reauthorization
Anti-VEGF prior auth is a recurring cycle, not a one-time approval, and it fails most often when the request just restates the original diagnosis instead of showing what the drug is doing. A request that survives review generally needs all of the following:
- ResponseDocumented treatment response — visual acuity stable or improved since the prior period.
- ImagingOCT trend showing central subfield thickness stable or reduced, not one isolated scan.
- Step historyFirst-line agent tried and failed, or contraindicated — required by many commercial and MA plans, not by traditional Medicare.
- IntervalTreatment interval consistent with the plan's protocol — a shorter request than the chart's own treat-and-extend pattern supports invites a second look.
Traditional fee-for-service Medicare does not impose step therapy the way a commercial or MA plan's medical policy can. Confirm the requirement against the specific plan on file, not against Medicare's rules, to keep a reauthorization from stalling a scheduled injection.
Bilateral injections and the modifier that goes with them
Same-day bilateral injections are reported either as two lines (RT and LT) or one line with modifier 50, and the correct convention is payer-specific — check the payer's preference rather than assuming. ⚠️ 67028's current MUE and bilateral indicator are published by CMS and revised regularly; this build could not confirm the current values against CMS's own MUE table and fee schedule files (both returned access errors to automated retrieval), so verify them in CMS's lookup tools before building a bilateral rule into a scrubber. The full RT/LT-versus-pricing-modifier sequencing rule is in our ophthalmology billing guide.
Do and don't
- Match the HCPCS code and NDC to the product physically administered, including the correct biosimilar.
- Compute units from the milligram dose against the code's own unit basis, not the vial size.
- Report JZ affirmatively on every no-waste single-dose-container line.
- Code the diagnosis to the specific laterality and activity/stage branch the chart supports.
- Don't default to JW out of habit on a claim where the entire vial was administered.
- Don't assume white-bagged drug lines are exempt from JW/JZ.
- Don't submit an unspecified-eye diagnosis when the chart documents laterality and activity status.
- Don't assume Medicare's step-therapy posture applies to a commercial or MA plan's reauthorization.
Anti-VEGF drug lines eating into your ophthalmology margin?
We'll audit a sample of your recent injection claims for HCPCS-to-product mismatches, JW/JZ gaps, and diagnosis specificity, and show what's recoverable.
Frequently asked questions
Do we have to try bevacizumab (Avastin) before Eylea or Vabysmo will be approved?
Often, yes. Many commercial and Medicare Advantage plans run step therapy for anti-VEGF drugs, requiring a documented bevacizumab trial before approving aflibercept, ranibizumab, or faricimab, and reauthorization typically requires proof of treatment response rather than automatic renewal. Traditional fee-for-service Medicare does not impose step therapy, so confirm the requirement against the specific plan on file before assuming a first-line trial is required.
How do we calculate JW waste units for a partial anti-VEGF vial?
Convert the discarded amount into the HCPCS code's own unit basis, and report it on a separate claim line with modifier JW. For example, if a vial is labeled 0.5 mg and the order calls for a 0.3 mg dose of ranibizumab (J2778, billed per 0.1 mg), the claim reports 3 units of J2778 for the dose given plus a second line, JW, with 2 units for the 0.2 mg discarded. If the full labeled amount was administered with nothing discarded, there is no waste line — report JZ instead, on the dose line itself.
Can we bill 67028 with modifier 50 for bilateral same-day injections, or do we need separate RT/LT lines?
Either can be correct, but the payer decides which — don't default without checking. Medicare's bilateral indicator for 67028 generally supports two lines (RT and LT) rather than a single line with modifier 50, while a number of commercial payers prefer the 50 convention used elsewhere in surgical billing. Submitting the wrong convention is a routine cause of one eye's line denying or underpaying while the other pays correctly, easy to miss since only half the claim looks wrong.
Verify before billing. CPT is a registered trademark of the American Medical Association; codes here are paraphrased, not reproduced from the CPT Professional edition. CPT, HCPCS and ICD-10 codes, coverage policy, and bundling edits change, including annual code-set updates. This page reflects standard industry practice and is provided for general education — it is not a substitute for your own compliance review, your current payer contracts, or the current-year code sets. Confirm requirements against your specific payer mix before submitting claims.